Severe hypoglycaemia in type 1 diabetes mellitus: underlying drivers and potential strategies for successful prevention

被引:37
作者
Little, S. A. [1 ]
Leelarathna, L. [2 ]
Barendse, S. M. [3 ]
Walkinshaw, E. [4 ]
Tan, H. K. [5 ]
Solomon, A. Lubina [4 ]
de Zoysa, N. [6 ]
Rogers, H. [6 ]
Choudhary, P. [6 ]
Amiel, S. A. [6 ]
Heller, S. R. [4 ]
Evans, M. [2 ]
Flanagan, D. [5 ]
Speight, J. [3 ,7 ,8 ]
Shaw, J. A. M. [1 ]
机构
[1] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[2] Univ Cambridge, Wellcome Trust MRC Inst Metab Sci Metab Res Labs, Cambridge, England
[3] AHP Res, Hornchurch, England
[4] Univ Sheffield, Sch Med & Biomed Sci, Sheffield, S Yorkshire, England
[5] Peninsula Coll Med & Dent, Plymouth, Devon, England
[6] Kings Coll London, Diabet & Nutr Sci Div, London WC2R 2LS, England
[7] Diabet Australia Vic, Australian Ctr Behav Res Diabet, Melbourne, Vic, Australia
[8] Deakin Univ, Sch Psychol, Ctr Mental Hlth & Wellbeing Res, Burwood, Australia
关键词
type; 1; diabetes; hypoglycaemia; impaired awareness of hypoglycaemia; INSULIN-PUMP THERAPY; BASAL-BOLUS REGIMEN; NEUTRAL PROTAMINE HAGEDORN; GLUCOSE MONITORING-SYSTEM; IMPROVED GLYCEMIC CONTROL; NPH INSULIN; NOCTURNAL HYPOGLYCEMIA; AUTONOMIC FAILURE; NEUROENDOCRINE RESPONSES; RECURRENT HYPOGLYCEMIA;
D O I
10.1002/dmrr.2492
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypoglycaemia remains an over-riding factor limiting optimal glycaemic control in type 1 diabetes. Severe hypoglycaemia is prevalent in almost half of those with long-duration diabetes and is one of the most feared diabetes-related complications. In this review, we present an overview of the increasing body of literature seeking to elucidate the underlying pathophysiology of severe hypoglycaemia and the limited evidence behind the strategies employed to prevent episodes. Drivers of severe hypoglycaemia including impaired counter-regulation, hypoglycaemia-associated autonomic failure, psychosocial and behavioural factors and neuroimaging correlates are discussed. Treatment strategies encompassing structured education, insulin analogue regimens, continuous subcutaneous insulin infusion pumps, continuous glucose sensing and beta-cell replacement therapies have been employed, yet there is little randomized controlled trial evidence demonstrating effectiveness of new technologies in reducing severe hypoglycaemia. Optimally designed interventional trials evaluating these existing technologies and using modern methods of teaching patients flexible insulin use within structured education programmes with the specific goal of preventing severe hypoglycaemia are required. Individuals at high risk need to be monitored with meticulous collection of data on awareness, as well as frequency and severity of all hypoglycaemic episodes. Copyright (c) 2013 John Wiley & Sons, Ltd.
引用
收藏
页码:175 / 190
页数:16
相关论文
共 141 条
[1]   The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients [J].
Ahmed, ABE ;
Home, PD .
DIABETES CARE, 1998, 21 (01) :32-37
[2]  
American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS110
[3]   EFFECT OF INTENSIVE INSULIN THERAPY ON GLYCEMIC THRESHOLDS FOR COUNTERREGULATORY HORMONE-RELEASE [J].
AMIEL, SA ;
SHERWIN, RS ;
SIMONSON, DC ;
TAMBORLANE, WV .
DIABETES, 1988, 37 (07) :901-907
[4]   RATE OF GLUCOSE FALL DOES NOT AFFECT COUNTERREGULATORY HORMONE RESPONSES TO HYPOGLYCEMIA IN NORMAL AND DIABETIC HUMANS [J].
AMIEL, SA ;
SIMONSON, DC ;
TAMBORLANE, WV ;
DEFRONZO, RA ;
SHERWIN, RS .
DIABETES, 1987, 36 (04) :518-522
[5]   Fear of hypoglycaemia in adults with Type 1 diabetes [J].
Anderbro, T. ;
Amsberg, S. ;
Adamson, U. ;
Bolinder, J. ;
Lins, P. -E. ;
Wredling, R. ;
Moberg, E. ;
Lisspers, J. ;
Johansson, U. -B. .
DIABETIC MEDICINE, 2010, 27 (10) :1151-1158
[6]  
[Anonymous], 1997, Diabetes, V46, P271
[7]   Hypoglycemia in the diabetes control and complications trial [J].
不详 .
DIABETES, 1997, 46 (02) :271-286
[8]  
[Anonymous], 2010, DIABETIC MED
[9]  
[Anonymous], 2008, Continuous Subcutaneous Insulin Infusion for the Treatment of Diabetes Mellitus: Technology Appraisal Guidance
[10]  
[Anonymous], DIABETIC MED S1